Nurix Therapeutics Shares Gain 14% On Initial Data From Early-Stage Study Of Lead Drug Candidate

Shares of Nurix Therapeutics, Inc. (NRIX) are gaining nearly 14% on Wednesday morning after the company announced initial data from the first Phase 1a dose escalation trial of its lead drug candidate NX-2127 in patients with relapsed or refractory B-cell malignancies.

NRIX is currently trading at $32.97, up $4.01 or 13.83%, on the Nasdaq, on a volume of 800 thousand shares, far above average volume of 310 thousand shares. The stock has traded between $21.53 and $52.38 in the 52 week period.

Initial data from the first two completed cohorts of 100 mg and 200 mg, which included a total of six patients, showed Bruton's tyrosine kinase (BTK) levels in peripheral blood significantly decreased in all patients in the trial starting on day 1 and remained suppressed throughout the dosing period.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT